GlassScriptPhysician profile
Barbara Jean L Ottley
NPI 1790768950
$115,690.32
in general payments reported to CMS, 2019-2025
39 companies · $38.45 in 2025
The $38.45 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,265 · 2020: $4,963 · 2021: $58K · 2022: $38K · 2023: $5,271 · 2024: $705 · 2025: $38.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,400 · Food and Beverage: $2,264 · Consulting Fee: $150 · Travel and Lodging: $115 · Education: $85.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,400.00 |
| Food and Beverage | $2,263.50 |
| Consulting Fee | $150.00 |
| Travel and Lodging | $115.28 |
| Education | $85.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32,831.77 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $32,808.10 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30,390.78 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11,451.20 | 2019-2024 | Austedo Xr, Ajovy, Austedo |
| Livanova USA, INC. | $1,605.83 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Emd Serono, INC. | $983.31 | 2019-2024 | Mavenclad |
| Biogen, INC. | $903.96 | 2020-2024 | Tysabri, Vumerity, Avonex |
| Pfizer INC. | $572.82 | 2019-2025 | |
| Genzyme Corporation | $555.83 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $330.59 | 2020-2023 | |
| Neurocrine Biosciences, INC. | $316.77 | 2019-2021 | |
| Celgene Corporation | $305.91 | 2021-2024 | Zeposia |
| Allergan, INC. | $278.61 | 2020-2021 | |
| Sk Life Science, INC. | $253.79 | 2021-2024 | |
| Amgen INC. | $249.13 | 2021-2024 | Uplizna |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Jean Ottley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.